文献速递抗栓抗凝管理药物不良反应与药物警戒药物相互作用

口服抗凝药联用DPP-4抑制剂与严重出血事件

Concomitant Use of Oral Anticoagulants With Oral Dipeptidyl Peptidase-4 Inhibitors and Serious Bleeding Events.
PubMed 文献 · Clin Pharmacol Ther · 2024-09-11

本研究基于美国大型数据库,采用自身对照病例系列和病例交叉设计,评估口服抗凝药(OAC)与DPP-4抑制剂(DPP-4i)联用是否增加严重出血风险。结果显示部分联用组合的数值估计升高,如华法林/利西普利+利格列汀的调整比值比为3.49(1.29-9.48),但因统计不精确未能确认既往信号,提示联用时需谨慎并进一步研究。

要点

  • 华法林/利西普利+利格列汀的严重出血调整RRR为3.49(1.29-9.48)。
  • 阿哌沙班/利西普利+沙格列汀的调整RRR为0.32(0.05-1.91)。
  • 部分联用组合数值升高,但统计不精确,需谨慎并进一步研究。

核心结论

  • 未能确认既往发现的OAC与DPP-4i联用严重出血信号,但多个数值升高的估计提示联用需谨慎并进一步研究。

研究设计与样本

  • 采用自身对照病例系列(SCCS)和病例交叉(CCO)设计,研究人群为2016-2020年同时暴露于DPP-4i和OAC或赖诺普利(阴性对照)的Medicare受益人。

主要发现

  • SCCS中,严重出血的调整RRR范围从阿哌沙班/赖诺普利+沙格列汀的0.32(0.05-1.91)到华法林/赖诺普利+利格列汀的3.49(1.29-9.48)。
  • CCO中,调整ROR范围从利伐沙班/赖诺普利+沙格列汀的0.01(0.00-0.20)到阿哌沙班/赖诺普利+利格列汀的2.99(0.74-12.11)。

临床怎么用

  • 临床对于OAC与DPP-4i联用,尤其华法林+利格列汀等数值升高组合,应保持 caution 并个体化评估出血风险。

局限性

  • 统计不精确,未能确认既往信号,部分估计值置信区间宽泛。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In a prior screening study, saxagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i), was found to have an increased rate of serious bleeding when used concomitantly with several oral anticoagulants (OACs). We aimed to confirm or refute the associations between concomitant use of individual OACs and DPP-4is and serious bleeding in a large US database, using self-controlled case series (SCCS) and case-crossover (CCO) designs. The study population was eligible Medicare beneficiaries co-exposed to a DPP-4i (precipitant) and either an OAC (object drug) or lisinopril (negative control object drug) in 2016-2020. For the SCCS, we used conditional Poisson regression to estimate adjusted rate ratios (RRs) between each co-exposure (vs. not) and serious bleeding and divided the RR by the adjusted RR for the corresponding lisinopril + precipitant pair to obtain ratios of RRs (RRRs). For the CCO, we estimated the adjusted odds ratios (ORs) of exposure to the precipitant in the focal window vs. referent window using multivariable conditional logistic regression and divided the ORs in the object drug-exposed cases over the ORs in negative object drug-exposed cases to obtain the ratios of ORs (RORs). The adjusted RRRs for serious bleeding ranged from 0.32 (0.05-1.91) for apixaban/lisinopril + saxagliptin to 3.49 (1.29-9.48) for warfarin/lisinopril + linagliptin. The adjusted RORs ranged from 0.01 (0.00-0.20) for rivaroxaban/lisinopril + saxagliptin to 2.99 (0.74-12.11) for apixaban/lisinopril + linagliptin. While we could not confirm previously identified signals because of statistical imprecision, several numerically elevated estimates still warrant caution in concomitant use and further examination.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Pham Nguyen TP, Leonard CE, Brensinger CM, et al. Concomitant Use of Oral Anticoagulants With Oral Dipeptidyl Peptidase-4 Inhibitors and Serious Bleeding Events. Clin Pharmacol Ther. 2024. PMID: 39262110. doi:10.1002/cpt.3442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。